FDA Approved: FILSPARI — Supplemental Application (Travere Therapeutics, Inc.)

View source ↗

Summary

The FDA has a supplemental application (AP) for Filspari (sparsentan) from Travere Therapeutics, Inc., currently under regulatory review. The submission concern…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• FILSPARI (SPARSENTAN)

Snippet

SUPPL AP for FILSPARI (SPARSENTAN)